DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases.
By restoring levels of the naturally occurring protein KLK1, DM199 therapy has the potential to improve circulation and overall function of critical systems, as well as reduce inflammation and oxidative stress. DiaMedica is focused on exploring this potential in acute ischemic stroke, preeclampsia, fetal growth restriction, and other diseases where promoting homeostasis and improving blood flow throughout the body is beneficial.
DM199 (rhKLK1) is a pharmacologically active recombinant form of KLK1 and represents an optimized, patent-protected formulation combining closely related isoforms with varying degrees of glycosylation, a critical component of the candidate's effectiveness.
A proprietary cell line technology efficiently and reliably produces large amounts of KLK1. The patent-protected manufacturing process covers all the vectors and reagents used to manufacture DM199 at scale.
DM199 composition of matter and delivery patents are protected until 2033. Worldwide dose, route of delivery, formulation and indication patents provide coverage to 2039 in the United States and globally.
